{"Novo Nordisk":{"tweets.background":"#F6F6F6","Synonym":"Novo Nordisk A\/S ","count":"5","Related disease":["Diabetes"],"CurationStatus":"curated","tweets.links":"#013C41","tweets.color":"#605C4F","RelatedTo":"Resource:EFPIA","shell.background":"#013C41","Address":["Headquarters: Novo Nordisk A\/S","Novo All\u00e9","2880 Bagsvaerd"],"SuperCategory":"Commercial Organization","Id":"nlx_158501","Species":"Human","user":"{{#show: {{FULLPAGENAME ","DefiningCitation":"http:\/\/www.novonordisk.com\/","Keywords":["Growth hormone therapy","Hormone replacement therapy","Pharmaceutical","Health care","Medicine","Device"],"Definition":"A Danish multinational pharmaceutical company that manufactures and markets pharmaceutical products and services. Key products include diabetes care medications and devices. Novo Nordisk is also involved with hemostasis management, growth hormone therapy and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, NovoLog, Novolin R, NovoSeven, NovoEight and Victoza. (Adapted from Wikipedia)"}}